Moderna's stock fell 19% due to market turbulence. Concerns about economic growth and market volatility impacted the biotech company. Investors retreated from risky investments, leading to Moderna's decline. The company faces challenges diversifying beyond COVID-19 products and maintaining investor confidence amidst long-term decline.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing